Theravance Biopharma, Inc. Cash and Restricted Cash
Theravance Biopharma, Inc. (TBPH) had Cash and Restricted Cash of $220.60 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-11
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $220.60M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $288.94M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $168.64M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $175.61M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $220.60M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $288.94M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $168.64M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $175.61M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $282.76M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $111.45M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $38.63M 10-Q · filed 2026-08-11 |
| 2024-09-30 | $24.21M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $47.18M 10-Q · filed 2025-08-13 |
| 2024-03-31 | $54.67M 10-Q · filed 2025-05-12 |
| 2023-12-31 | $40.38M 10-K · filed 2026-03-23 |
| 2023-09-30 | $72.52M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $106.43M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $188.50M 10-Q · filed 2024-05-15 |
| 2022-12-31 | $299.01M 10-K · filed 2025-03-07 |
| 2022-09-30 | $419.37M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $88.13M 10-Q · filed 2023-08-09 |
| 2022-03-31 | $95.20M 10-Q · filed 2023-05-10 |
| 2021-12-31 | $90.80M 10-K · filed 2024-03-01 |
| 2021-09-30 | $122.26M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $205.78M 10-Q · filed 2022-08-08 |
| 2021-03-31 | $114.84M 10-Q · filed 2022-05-06 |
| 2020-12-31 | $82.30M 10-K · filed 2023-03-01 |
| 2020-09-30 | $94.11M 10-Q · filed 2021-11-08 |
| 2020-06-30 | $105.57M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $333.63M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $58.90M 10-K · filed 2023-03-01 |
| 2019-09-30 | $110.73M 10-Q · filed 2020-11-09 |
| 2019-06-30 | $179.14M 10-Q · filed 2020-08-10 |
| 2019-03-31 | $224.07M 10-Q · filed 2020-05-08 |
| 2018-12-31 | $378.85M 10-K · filed 2022-02-28 |
| 2018-09-30 | $102.03M 10-Q · filed 2019-11-08 |
| 2018-06-30 | $104.69M 10-Q · filed 2019-08-05 |
| 2018-03-31 | $126.66M 10-Q · filed 2019-05-10 |
| 2017-12-31 | $89.81M 10-K · filed 2021-02-26 |
| 2017-09-30 | $92.13M 10-Q · filed 2018-11-08 |
| 2017-06-30 | $140.46M 10-Q · filed 2018-08-02 |
| 2016-12-31 | $345.54M 10-K · filed 2020-02-27 |
| 2015-12-31 | $113.54M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |